PEN vs RMD
PEN: Penumbra is a medical device innovator specializing in mechanical thrombectomy and embolization technologies to treat neurovascular and peripheral vascular conditions. RMD: ResMed is a leader in connected medical technology providing digital health solutions and innovative devices to improve the lives of people with sleep-disordered breathing and chronic respiratory conditions.
Side-by-side fundamentals
| Metric | PEN | RMD | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $324.66 | $211.94 | |
| Market cap as of 2026-08-09 | $12.8B | $30.7B | |
| P/E as of 2026-08-09 | 79.63 | 20.23 | RMD lower |
| PEG as of 2026-08-09 | 10.01 | 2.20 | RMD lower |
| Net margin as of 2026-08-09 | +10.7% | +27.4% | RMD higher |
| Gross margin as of 2026-08-09 | +67.8% | +61.6% | PEN higher |
| Operating margin as of 2026-08-09 | +12.4% | +34.2% | RMD higher |
| ROE as of 2026-08-09 | +11.1% | +24.4% | RMD higher |
| ROA as of 2026-08-09 | +8.6% | +18.0% | RMD higher |
| Debt / equity as of 2026-08-09 | 0.01 | 0.10 | PEN lower |
| Revenue growth (YoY) as of 2026-08-09 | +17.6% | +10.3% | PEN higher |
| Revenue CAGR (3y) SEC XBRL | +18.3% | +12.9% | PEN higher |
| Dividend yield as of 2026-08-09 | n/a | +1.2% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-09 | 0.70 | 0.73 | |
| 1-year return as of 2026-08-07 close | +34.9% | -24.4% | PEN higher |
Fundamentals: market data, as of 2026-08-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.